Less intense surveillance OK for some prostate cancer cases

December 23, 2016

(HealthDay)—Certain patients on active surveillance for prostate cancer may be eligible for less intensive surveillance, according to a study published in the January issue of The Journal of Urology.

Evan Kovac, M.D., from the Cleveland Clinic, and colleagues identified 300 men on from a prospective database; the men had undergone initial surveillance prostate biopsy, with or without confirmatory biopsy, within one year of diagnosis. Eighty-seven percent were classified as having National Comprehensive Cancer Network very-low-risk or low-risk at diagnosis. The presence of 50 percent or more positive cores and/or surveillance prostate biopsy Gleason score upgrading was used to define disease reclassification on active surveillance.

The researchers found that 16 and 6 percent of patients had type I and II reclassification, respectively, at the time of initial surveillance prostate biopsy. The rates of type I and type II reclassification at initial surveillance prostate biopsy were reduced for those who underwent confirmatory biopsy (9 versus 23 percent [P = 0.001] and 3 versus 9 percent [P = 0.01], respectively). The two-year rates of subsequent type I and II reclassification were 17 and 3 percent, respectively, for the 251 without disease reclassification at initial surveillance prostate biopsy.

"Patients on active surveillance with stable disease at the time of initial surveillance prostate biopsy may be appropriate candidates for less intensive surveillance schedules," the authors write.

One author disclosed financial ties to Cook and Healthtronics.

Explore further: MRI has a role to play after negative prostate biopsy

More information: Full Text

Related Stories

MRI has a role to play after negative prostate biopsy

December 16, 2016
(HealthDay)—Magnetic resonance imaging (MRI) and MRI-targeted biopsies have a role in the diagnosis and treatment of patients with a prior negative prostate biopsy, according to a review published in the December issue ...

Diagnostic factors may help patients avoid prostate biopsy

January 4, 2016
(HealthDay)—Initial diagnostic characteristics may be able to identify men initiating active surveillance who could avoid confirmatory biopsy, according to a study published in the January issue of The Journal of Urology.

Guidelines developed for prostate MRI after negative biopsy

November 18, 2016
(HealthDay)—In a consensus statement from the American Urological Association and Society of Abdominal Radiology, published in the December issue of The Journal of Urology, guidelines are presented for prostate magnetic ...

Added prostate CA criteria may help ID surveillance candidates

January 24, 2014
(HealthDay)—Additional predictors, such as prostate-specific antigen (PSA) density and extent of cancer on biopsy, help guide selection of prostate cancer patients for active surveillance programs, according to research ...

MRI helps identify patients with prostate cancer who may benefit from active surveillance

September 24, 2012
PSA screening has resulted in improved prostate cancer survival, but the high rate of diagnosis and treatment side effects raise concerns about overtreatment. In the quest to prevent overtreatment, "active surveillance" has ...

Repeat prostate biopsy rounds yield cancer cases

April 13, 2015
(HealthDay)—Among a group of men with an initial negative prostate biopsy, clinically significant cancer is still found in subsequent repeat sampling rounds, according to a study published in the April issue of The Journal ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.